F-FES PET能否成为转移性HR+/HER2-患者治疗选择的新驱动因素？
Could F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2- Patients?
作者信息
Sanò Maria Vita, Russo Alessandro, Marino Lorenza, Pafumi Sarah, Di Pietro Martina, Ricciardi Giuseppina Rosaria Rita
机构信息
Department of Medical Oncology, Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy.
Department of Biomedical Sciences, Humanitas University, 20027 Pieve Emanuele, Italy.
出版信息
Diagnostics (Basel). 2025 Aug 25;15(17):2139. doi: 10.3390/diagnostics15172139.
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer is the most prevalent subtype. Positron emission tomography (PET) imaging with 16α-18F-fluoro-17β-fluoroestradiol (F-FES), a radiolabeled form of estradiol, enables the assessment in vivo of ER expression, ER heterogeneity in metastatic sites and functionally active ER capable of ligand binding. This imaging modality has been recently approved as a diagnostic tool for detecting ER-positive lesions in patients with recurrent or metastatic breast cancer. Despite promising activity, the role of this powerful tool is still debated. Herein we critically analyzed current evidence supporting the use of 18F-FES PET in metastatic ER+/HER2- breast cancer, highlighting the potential challenges for clinical implementation.
激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌是最常见的亚型。使用16α-18F-氟-17β-氟雌二醇（F-FES，一种雌二醇的放射性标记形式）进行正电子发射断层扫描（PET）成像，能够在体内评估雌激素受体（ER）表达、转移部位的ER异质性以及能够结合配体的功能活性ER。这种成像方式最近已被批准作为检测复发性或转移性乳腺癌患者ER阳性病变的诊断工具。尽管具有可观的活性，但这种强大工具的作用仍存在争议。在此，我们批判性地分析了支持在转移性ER+/HER2-乳腺癌中使用18F-FES PET的现有证据，突出了临床应用中的潜在挑战。
Zotero 插件